Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Immunology Stem cell transplantation: Stem cell transplantation:

Stem cell transplantation - Translational

 
Mirjam Belderbos
 
The authors of the abstract conclude: 
This study provides comprehensive data on the clonal dynamics of unmanipulated HSPCs in human recipients. The observation that the HSCT recipient acquires the ‘mutational age’ of his/her donor may be especially relevant for young recipients of old donors, which will be subject of further studies.
————————————————————————————————————————————————————————
 
 
Laura Dillon, Gege Gui, Brent Logan, et al.
 
The authors of the abstract conclude: 
This study provides evidence that post-transplant relapse rates in MDS patients are highest in those with pre-transplant genomic evidence of high-risk disease. In those testing positive, randomization to myeloablative conditioning lowered but did not eliminate relapse risk.
————————————————————————————————————————————————————————
 
 
Antonio Galleu, Malte von Bonin, Dragana Milojkovic, et al.
 
The authors of the abstract conclude: 
Our data strongly support the notion that achieving a response to MSC is crucially important to improve the outcome of sr-GvHD. Here we show that responders exhibit in vitro cytotoxic activity against MSC and that our cytotoxic assay is a reliable predictor of clinical response. We also provide evidence that MEP may reduce the cytotoxic activity and can consequently impact on clinical responses when used before MSC treatment 
————————————————————————————————————————————————————————
 
 
Virginia Escamilla Gómez, Alfonso Rodríguez Gil, Estefanía García Guerrero, et al.
 
The authors of the abstract conclude: 

Ruxolitinib favors the increase of Treg percentages along time after T cell activation in cell culture. Ruxolitinib does not hamper the suppressive capacity of Tregs using in vitro assays.

The combined treatment of cGvHD with Tregs and Ruxolitinib outperforms the individual treatments in terms of survival and clinical score in our mouse model. Infused Tregs can be detected as late as 18 weeks after infusion in the bone marrow of treated mice.

The infusion of Tregs in cGvHD patients treated with Ruxolitinib is safe and allows both to decrease in the immunosuppressive treatment and shows improvement in GVHD clinical score.

————————————————————————————————————————————————————————
 
 
Xiao Liu, Yan Su, Xiao-jun Huang, Xiao-hui Zhang
 
The authors of the abstract conclude: 
Our results demonstrated an imbalance of macrophage polarization towards the M1 phenotype in GVHD mice. ATO treatment ameliorated GVHD and adjusted the M1/M2 balance. We further verified the role of ATO in RAW264.7 cells and macrophages induced from aGVHD patients in vitro and found that ATO could modulate macrophage polarization towards the M2 phenotype. This study may shed light on new mechanisms of aGVHD pathogenesis and provide a basis for the preventive and therapeutic potential of ATO in aGVHD patients.